Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Primary:
• To compare the safety profile of a single intravenous administration of AVP-21D9 as
compared with Placebo
Secondary:
- To evaluate the pharmacokinetics (PK) of a single intravenous administration of AVP-21D9
- To evaluate the immunogenicity of AVP-21D9